In a bid to lower its costs for hepatitis C medicines, Louisiana officials are exploring a novel approach in which the state would make subscription-based payments to drug makers.

Essentially, the state would agree to pay a fixed amount of money over several years for unlimited access to medication for anyone who is enrolled in the state Medicaid program or incarcerated in a state prison. Some details need to be worked out, but payments to one or more companies would be equal to or less than what the state is currently spending to provide hepatitis C medicines to these populations.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy